Article thumbnail

Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549

By Wei Zhang, Jing Zhu, Jing Bai, Hui Jiang, Fangli Liu, An Liu, Peng Liu, Guohua Ji, Rongwei Guan, Donglin Sun, Wei Ji, Yang Yu, Yan Jin, Xiangning Meng and Songbin Fu
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2897778
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Ananthaswamy HN: Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.
  2. (2008). Anti-apoptotic therapy with a Tat fusion protein protects against excitotoxic insults in vitro and in vivo. Exp Neurol
  3. (2001). Cao SL: The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines.
  4. (2008). Casartelli C: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors. Genet Mol Res
  5. (2003). Cell cycle and cancer.
  6. (1999). Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.
  7. (1998). Cowan K: Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene
  8. (2007). Effects of exogenous p16(ink4a) gene on biological behaviors of human lung cancer cells. J Huazhong Univ Sci Technolog Med Sci
  9. (2001). Growth inhibition of transfection of p16 gene to lung adenocarcinoma cell lines Anip973 and AGZY83-a.
  10. (2006). H: Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract
  11. (1999). Huang DP: Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma.
  12. (1995). Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res
  13. (2007). Hwang HT: Cisplatin-induced senescence and growth inhibition in human non-small cell lung cancer cells with ectopic transfer of p16INK4a. Oncol Res
  14. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res
  15. (1999). Jr: The emerging p53 gene family.
  16. (2000). Ling Z: Different effects of p16 gene on human glioma cell lines through different transfection methods. Ai Zheng
  17. (2006). M: p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun
  18. (2003). Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer Genet Cytogenet
  19. (2003). Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr Protein Pept Sci
  20. (2001). Rutka JT: The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth.
  21. (2009). S: PTD4-apoptin protein therapy inhibits tumor growth in vivo.
  22. (2001). Sedivy JM: Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol
  23. (1999). SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science
  24. (1994). Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science
  25. (2008). Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis.
  26. (1999). Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene
  27. (2002). Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol
  28. (2005). Tsao H: Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
  29. (2005). WQ: The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity. Colloids Surf B Biointerfaces